Cardiovascular Systems (FRA:R7Y1) Valuation Rank

View and export this data going back to 2012. Start your Free Trial

What is Cardiovascular Systems Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Cardiovascular Systems Valuation Rank Related Terms

Thank you for viewing the detailed overview of Cardiovascular Systems's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiovascular Systems (FRA:R7Y1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cardiovascular Systems Inc (FRA:R7Y1) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

1225 Old Highway 8 Northwest, Saint Paul, MN, USA, 55112-6416

Website

https://www.csi360.com

Cardiovascular Systems Inc is a medical technology company focused on patients with peripheral and coronary artery diseases. Its peripheral artery disease systems are catheter-based platforms used to treat plaque in leg arteries above and below the knee. The firm's orbital atherectomy systems are used in peripheral and coronary commercial applications. Its OAS products include the Diamondback 360 Peripheral and Stealth 360 systems. Sales of Peripheral OAS contribute the majority of revenue. Cardiovascular systems generate the vast majority of its revenue in the United States.